Abicipar pegol

Drug Profile

Abicipar pegol

Alternative Names: AGN-150998; Anti-VEGF DARPin®; DARPin® anti-VEGF product for eye disorders - Molecular Partners/Allergan; MP 0112

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Molecular Partners AG
  • Developer Allergan; Molecular Partners AG
  • Class Eye disorder therapies; Peptides; Polyethylene glycols; Proteins
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase II Diabetic macular oedema

Most Recent Events

  • 01 Dec 2016 Allergan initiates enrolment in a phase I trial for Macular degeneration in USA (Intravitreous) (NCT02859766)
  • 27 Oct 2016 Interim efficacy and adverse events data from a phase II trial in Diabetic macular oedema released by Molecular Partners
  • 04 Aug 2016 Allergan plans a phase I trial in Macular degeneration in USA (NCT02859766)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top